Q
QuantAbundance

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

31,229 signal articles · 0 in last 24h · 160,153 total before filter · latest 1d ago
0last 24h
614last 7d
87● bullish (7d)
65● bearish (7d)
214publishers
AllMacro118Earnings166M&A63Regulatory12Product10Analyst17
✕ clear all filtersSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
Moderna (MRNA): Buy, Sell, or Hold Post Q1 Earnings?
StockStory77d agoneutral
Moderna (MRNA): Buy, Sell, or Hold Post Q1 Earnings?

The past six months have been a windfall for Moderna’s shareholders. The company’s stock price has jumped 46.4%, hitting $62.97 per share. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.

Tesla rides robotaxi momentum into earnings season
Proactive77d agoneutral
Tesla rides robotaxi momentum into earnings season

Tesla Inc (NASDAQ:TSLA) is heading into its second-quarter earnings report with robotaxis doing most of the talking. Bank of America reiterated its Buy rating on the stock and $460 price objective, pointing to the service's rapid expansion, a delivery number that blew past Wall Street...

Do Rising Earnings Estimates Reframe Albemarle’s (ALB) Lithium Strategy as Discipline or Cyclicality?
Simply Wall St.77d agoneutral
Do Rising Earnings Estimates Reframe Albemarle’s (ALB) Lithium Strategy as Discipline or Cyclicality?

In recent weeks, Albemarle has attracted heightened attention as analysts lifted earnings estimates for the current quarter and fiscal years, ahead of its August 5, 2026 earnings release. This shift in expectations, reflected in a strong Zacks Rank #2 (Buy) and growing search interest, underscores how sentiment can pivot despite recent volatility and selling pressure. We’ll now examine how this wave of upward earnings estimate revisions could reshape Albemarle’s existing investment...